Panel reviews clinical trial landscape and new strategies for recurrent endometrial cancer after checkpoint inhibitor failure
read at onclive ↗Neutral
A recent expert panel has examined the current state of clinical trials targeting recurrent endometrial cancer.
The discussion highlighted that many patients now face disease progression after receiving frontline checkpoint inhibitor therapies, creating a need for new options.
The panel outlined several emerging therapeutic approaches under investigation, including novel combinations and next generation agents, and identified key trials that may shape future treatment pathways.
source
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer”
read at onclive ↗
comments(0)
5-min edit window · permanent after that